Anavex Life Sciences(DE:12X1)
€0.62-0.10 (-14.48%)
DE:12X1
Anavex Life Sciences stock drug pipeline
€0.62
At close:-0.10 (-14.48%)
Anavex Life Sciences (12X1) Drug Pipeline
2 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Anavex3-71 Oral Capsules | Schizophrenia | Phase II | Active Not Recruiting | A Study of ANAVEX3-71 in Adults With Schizophrenia | Jan 19, 2024 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Anavex3-71 Oral Capsules | Phase II | Schizophrenia | Active Not Recruiting | A Study of ANAVEX3-71 in Adults With Schizophrenia | Jan 19, 2024 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Anavex Life Sciences (DE:12X1) have in its pipeline
Anavex Life Sciences DE:12X1 is currently developing the following drugs: Anavex3-71 Oral Capsules. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

